Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabrò A
Department of 1st Medical Pathology, University of Padua, Italy.
Drugs Exp Clin Res. 1992;18(5):189-95.
The aim of this study was to verify the effects of oral administration of a new enteric-coated formulation of sulodexide on blood viscosity and fibrinolysis. Six outpatients suffering from peripheral artery occlusive disease were administered orally two enteric-coated tablets containing 50 mg of sulodexide, twice daily for seven days. On the first and seventh administration days, the following parameters were evaluated: plasminogen activator inhibitor (PAI-1) activity, PAI-1 antigen, tissue plasminogen activator (t-PA) and whole blood, serum and plasma viscosity, before (0 time) and 2, 4 and 8 hours after ingestion of the drug. Following the first administration (50 mg), a slight reduction of PAI was registered; after 7 days' administration, a clear-cut lowering of functional and antigenic PAI was observed, together with an increase of t-PA. As to the drug's influence on blood viscosity, after 7 days the most evident reduction was that registered for plasma viscosity. No side effects were observed throughout the treatment period.
本研究的目的是验证口服一种新的肠溶衣剂型舒洛地昔对血液粘度和纤维蛋白溶解的影响。六名患有外周动脉闭塞性疾病的门诊患者口服两片含50mg舒洛地昔的肠溶衣片，每日两次，共七天。在首次给药日和第七给药日，评估以下参数：纤溶酶原激活物抑制剂（PAI-1）活性、PAI-1抗原、组织纤溶酶原激活物（t-PA）以及全血、血清和血浆粘度，在服药前（0时）以及服药后2、4和8小时。首次给药（50mg）后，PAI略有降低；给药7天后，观察到功能性和抗原性PAI明显降低，同时t-PA增加。至于药物对血液粘度的影响，7天后最明显的降低是血浆粘度。在整个治疗期间未观察到副作用。
